Hims & Hers (HIMS) Stock Rockets 44% on Surprise Novo Nordisk Partnership Deal

TLDR

• Shares of Hims & Hers (HIMS) exploded over 44% during premarket hours Monday following a Bloomberg report that Novo Nordisk will distribute weight-loss medications through its platform
• An official partnership announcement between the companies may arrive as soon as Monday
• This agreement represents a dramatic shift after Novo initiated legal action against Hims in February regarding a competing oral Wegovy product
• Leerink’s Michael Cherny described the news as “both a surprise and an unabashed positive for HIMS’ stock” while maintaining a Market Perform rating
• Morgan Stanley analyst Craig Hettenbach suggested the partnership might alleviate legal and regulatory concerns that had pressured the significantly shorted stock

Shares of Hims & Hers Health (HIMS) skyrocketed more than 44% during premarket trading Monday following a Bloomberg report indicating Novo Nordisk intends to distribute its weight-loss medications via the Hims platform.

According to the report, a formal announcement may be released as early as Monday. The revelation propelled HIMS shares dramatically higher, while Novo’s Copenhagen-traded shares advanced approximately 1%.

Hims & Hers Health, Inc., HIMS

The surge represents a dramatic reversal for shares that had already tumbled roughly 51% year-to-date prior to Monday’s rally.

Under the arrangement, Novo’s obesity medications — encompassing products associated with its Ozempic and Wegovy franchises — would become available directly through the Hims platform. This marks a significant pivot considering the contentious relationship between the companies in recent months.

Novo initiated litigation against Hims in February following the telehealth firm’s introduction of a competing version of Novo’s oral Wegovy weight-loss medication. Novo contended the product violated patents protecting its bestselling treatments.

The legal action represented just one chapter in their ongoing dispute. Novo had previously challenged Hims for allegedly continuing to promote compounded alternatives of its medications following an earlier disagreement.

Analyst Reaction

Craig Hettenbach from Morgan Stanley shared a comparable perspective. He indicated the partnership might remove one of the most significant obstacles facing HIMS — the regulatory and legal uncertainties surrounding its weight-loss operations.

Background on Compounded Drugs

Telehealth platforms like Hims gained the ability to distribute more affordable compounded alternatives of Novo and Eli Lilly weight-loss treatments during supply shortage periods affecting the branded products.

These supply constraints have since been resolved. Regulators anticipated compounding activities would cease, yet certain telehealth providers continued operations by modifying dosages or formulations in attempts to distinguish their offerings from branded alternatives.

This strategy placed Hims in Novo’s legal sights earlier this year.

The newly reported agreement, pending confirmation, would fundamentally transform that dynamic — converting Hims from a rival into a distribution channel for Novo’s medications.

Novo’s Copenhagen-listed shares traded approximately 1% higher on the developments as of early Monday morning.

The post Hims & Hers (HIMS) Stock Rockets 44% on Surprise Novo Nordisk Partnership Deal appeared first on Blockonomi.